Figures & data
Table 1 Characteristics of patients at baseline
Figure 1 Scatter plot of specific IgG4 antibodies versus DAS28.
![Figure 1 Scatter plot of specific IgG4 antibodies versus DAS28.](/cms/asset/5171c8df-2ff7-4a41-9d9a-3e6bafe9e7fd/dbtt_a_69606_f0001_c.jpg)
Figure 2 IgG4 specific antibodies against three different TNF blocking agents and DAS28.
![Figure 2 IgG4 specific antibodies against three different TNF blocking agents and DAS28.](/cms/asset/d91e84de-3c96-40d3-bedd-1de520318aaa/dbtt_a_69606_f0002_c.jpg)
Figure 3 Correlation between IgG4 specific antibodies, adverse effects and DAS28.
![Figure 3 Correlation between IgG4 specific antibodies, adverse effects and DAS28.](/cms/asset/2dc98d81-e6e3-495c-b936-e06a91fdf1bf/dbtt_a_69606_f0003_c.jpg)
Figure S1 Power calculations.
Notes: Power calculation reporting power (1-beta) vs sample size (number of pairs) under the assumption of a correlation coefficient ranging from 0.4 to 0.6 (moderate weak to moderate strong) with a null correlation of 0.1 and 0.05 for the left and the right panels respectively.
![Figure S1 Power calculations.Notes: Power calculation reporting power (1-beta) vs sample size (number of pairs) under the assumption of a correlation coefficient ranging from 0.4 to 0.6 (moderate weak to moderate strong) with a null correlation of 0.1 and 0.05 for the left and the right panels respectively.](/cms/asset/83902f72-74d8-4ea4-aac1-075f5e178838/dbtt_a_69606_sf0001_b.jpg)